Patients with Previously Untreated Advanced BRAF V600 Wild-Type MelanomaStatus: open
A Phase III, Open-Label, Multicenter, Two-Arm, Randomized Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab Versus Pembrolizuman in Patients with Previously Untreated Advanced BRAF V600 Wild-Type Melanoma
Treatment for Melanoma
This is a Phase III, multicenter, open-label, randomized study designed to evaluate the efficacy, safety, and pharmacokinetics of cobimetinib plus atezolizumab compared with pembrolizumab in treatment-naive participants with advanced BRAFV600 wild-type melanoma.
SponsorsThis trial is sponsored by Hoffmann-La Roche.
Interested in Clinical Trial?
Providers Associated With This Trial
- Arthur Edward Frankel, M.D.Medical OncologistChief of Medical Oncology; Arlene and Mayer Mitchell Chair of Medical Oncology
- Sachin Pai, MBBS, M.D.Medical OncologistProgram Leader of Developmental Therapeutics; Assistant Professor of Interdisciplinary Clinical Oncology